

BioLife Solutions and STEMCELL Technologies Announce Worldwide Distribution Agreement

Deal Expands Access to Best-in-Class HypoThermosol® and CryoStor™ Biopreservation Media Products via Sub-Distributor Network in Over 70 Countries

PRNewswire-FirstCall
BOTHELL, Wash.

BioLife Solutions, Inc. (BULLETIN BOARD: BLFS), a leading manufacturer and marketer of biopreservation tools for cells, tissues, and organs, today announced that it has entered into a non-exclusive distribution agreement with STEMCELL Technologies, Inc., based in Vancouver, Canada. STEMCELL Technologies, a member of the StemCell Group of companies, is a leading provider of products that support innovative research in hematology, immunology, cancer research, developmental biology, and many other areas of life science research.

Mike Rice, BioLife's chairman and CEO, noted, "We're very pleased to now have our products represented and distributed throughout the world by STEMCELL Technologies and their sub-distributor partners. Their MethoCult reagent systems have become worldwide standards and we look forward to their distribution network's ability to help our HypoThermosol and CryoStor product platforms achieve the same level of product adoption."

Allen Eaves M.D., Ph.D., founder of STEMCELL Technologies and Chairman of the StemCell Group, commented on the addition of BioLife's products to their reagents and media portfolio by stating, "Our interest in BioLife Solutions has grown as we've seen their products adopted by numerous customers in our strategic markets. We also conducted several comparative cell preservation experiments with CryoStor against other freeze media and were very impressed by the performance of CryoStor in improving post-thaw cell viability and recovery. We feel that the robust regulatory and quality footprint of serum-free and protein-free CryoStor and HypoThermosol will increasingly be valued by researchers and clinicians around the world."

About BioLife Solutions

BioLife Solutions develops, manufactures, and markets patented hypothermic storage/transport and cryopreservation media products for cells, tissues, and organs. The Company's proprietary HypoThermosol and CryoStor™ platform of biopreservation media products are marketed to academic research institutions, hospitals, and commercial companies involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife's GMP products are serum-free and protein-free, fully defined, and pre-formulated to reduce preservation-induced, delayed-onset cell damage and death. Comprehensive small animal intravenous safety studies have been completed on HypoThermosol and CryoStor, and both products are supported by US FDA Master Files. BioLife's enabling technology provides research and clinical organizations significantly enhanced post-preservation cell and tissue viability and function. For more information please visit www.biolifesolutions.com.

About STEMCELL Technologies

STEMCELL Technologies is a life sciences company dedicated to providing a range of products that support innovative research in hematology, immunology, cancer research, developmental biology, and many other areas of life science research. STEMCELL's specialized media and cell separation products are available for a wide range of research applications, and are complemented by a diverse array of cytokines, antibodies, and tissue culture reagents for use in research. Driven by science and enabled by close interactions with global leaders in cell biology and medicine, STEMCELL delivers over 900 products to research scientists in more than 70 countries worldwide. For more information please visit www.stemcell.com.

This news release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements include any statements that relate to the intent, belief, plans or expectations of the Company or its management, or that are not a statement of historical fact. Any forward-looking statements in this news release are based on current expectations and beliefs and are subject to numerous risks and uncertainties that could cause actual results to differ materially. Some of the specific factors that could cause BioLife Solutions' actual results to differ materially are discussed in the Company's recent filings with the Securities and Exchange Commission. BioLife Solutions disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Media Relations:
Len Hall
Allen & Caron Inc
(949) 474-4300
len@allencaron.com

Investor Relations:
Matt Clawson
Allen & Caron Inc
(949) 474-4300
matt@allencaron.com

First Call Analyst:
FCMN Contact:

SOURCE: BioLife Solutions, Inc.

CONTACT: Media Relations, Len Hall, len@allencaron.com, or Investor Relations, Matt Clawson, matt@allencaron.com, both of Allen & Caron Inc, for BioLife Solutions, Inc.

Web Site: <http://www.biolifesolutions.com/>
<http://www.stemcell.com/>

<https://investors.biolifesolutions.com/2009-08-17-BioLife-Solutions-and-STEMCELL-Technologies-Announce-Worldwide-Distribution-Agreement>